Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 2/5 cls
Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) Wedbush Y. Katherine Xu Upgrade Market outperform (from neutral) 1% $2.38
Xu cited increased confidence Achillion will partner ACH-1625, a selective inhibitor of HCV NS3 protease in Phase Ib testing. She said Phase Ib data showed that ACH-1625's potency as a single agent was at the high end of competitor HCV protease inhibitors in the clinic (see BioCentury, Jan. 18, 2010).
Acorda Therapeutics Inc. (NASDAQ:ACOR) Baird Christopher Raymond Downgrade Neutral (from market outperform) 9% $30.62
Deutsche Bank Mark Schoenebaum Price target Buy

Read the full 1275 word article

User Sign In